These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 19417672

  • 1. Serum and pleural fluid biomarkers for mesothelioma.
    Creaney J, Robinson BW.
    Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
    Pantazopoulos I, Boura P, Xanthos T, Syrigos K.
    Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
    [Abstract] [Full Text] [Related]

  • 3. Biomarkers for mesothelioma.
    Scherpereel A, Lee YC.
    Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
    [Abstract] [Full Text] [Related]

  • 4. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.
    Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
    [Abstract] [Full Text] [Related]

  • 5. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 9. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.
    Lung Cancer; 2008 Aug 15; 61(2):235-43. PubMed ID: 18281122
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.
    Cancer Epidemiol Biomarkers Prev; 2009 Feb 15; 18(2):646-50. PubMed ID: 19190155
    [Abstract] [Full Text] [Related]

  • 11. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.
    Clin Cancer Res; 2008 Mar 01; 14(5):1431-7. PubMed ID: 18316566
    [Abstract] [Full Text] [Related]

  • 12. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.
    J Thorac Oncol; 2008 Aug 01; 3(8):851-7. PubMed ID: 18670302
    [Abstract] [Full Text] [Related]

  • 13. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
    Lung Cancer; 2008 Oct 01; 62(1):45-54. PubMed ID: 18394747
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.
    Lung Cancer; 2011 Oct 01; 74(1):55-60. PubMed ID: 21397972
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
    Creaney J, Dick IM, Robinson BW.
    Curr Opin Pulm Med; 2015 Jul 01; 21(4):352-6. PubMed ID: 26016578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.